Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

23. Februar 2026 08:00 ET | Quelle: Cerevance, Inc.

Cerevance to Participate in the TD Cowen 46th Annual Health Care Conference

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing targeted therapies for neurodegenerative diseases and obesity, today announced participation...
05. Dezember 2025 21:00 ET | Quelle: Cerevance, Inc.

Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinson’s Disease

Phase 2 results selected as one of only 10 featured presentations in the Poster Tour at the 2025 Parkinson Study Group (PSG) Annual MeetingPivotal Phase 3 ARISE trial evaluating solengepras as an...
01. Dezember 2025 08:00 ET | Quelle: Cerevance, Inc.

Cerevance to Participate in RBC Capital Markets 2025 Healthcare Private Company Conference

Cerevance to Participate in RBC Capital Markets 2025 Healthcare Private Company Conference
24. November 2025 08:00 ET | Quelle: Cerevance, Inc.

Cerevance to Highlight Potential of Solengepras in Parkinson’s Disease at the 2025 Parkinson Study Group Annual Meeting

Cerevance to Highlight Potential of Solengepras in Parkinson’s Disease at the 2025 Parkinson Study Group Annual Meeting
17. November 2025 08:00 ET | Quelle: Cerevance, Inc.

Cerevance to Participate in the TD Cowen Treatment Advancements in Obesity and Related Disorders Summit

Cerevance to Participate in the TD Cowen Treatment Advancements in Obesity and Related Disorders Summit
22. September 2025 08:00 ET | Quelle: Cerevance, Inc.

Cerevance to Present Phase 2 Data on Solengepras in Parkinson’s Disease at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Cerevance to Present Phase 2 Data on Solengepras in Parkinson’s Disease at the 2025 International Congress of Parkinson's Disease and Movement Disorders
12. August 2025 08:00 ET | Quelle: Cerevance, Inc.

Cerevance to Participate in Piper Sandler Virtual CNS Symposium

Cerevance to Participate in Piper Sandler Virtual CNS Symposium
11. Juli 2025 08:00 ET | Quelle: Cerevance, Inc.

Cerevance Announces Presentations at the Alzheimer's Association International Conference 2025

AAIC Curtain Raiser
08. April 2025 11:00 ET | Quelle: Cerevance, Inc.

Cerevance Presents Positive Results from Phase 1 Study of CVN293 at American Academy of Neurology 2025 Annual Meeting

CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of KCNK13 inhibitors for neurodegenerative diseases characterized by...
01. April 2025 08:15 ET | Quelle: Cerevance, Inc.

Cerevance Presents Topline Results from Phase 2 ASCEND Trial of Solengepras as Monotherapy Treatment for Early-Stage Parkinson’s Disease at AD/PD 2025

Solengepras showed evidence of potential benefit in functional and non-motor symptoms versus placebo as measured by MDS-UPRDS Parts I, II, NMSS, and ESS, consistent with its novel non-dopaminergic...

Nächste Seite